1. Giovannini M, Agostoni C, Salari PC. Is carnitine essential in children? J Int Med Res 1991;19:88-102.
2. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo-controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569-72.
3. Canale C, Terrachini V, Biagini A, et al. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracing. Int J Clin Pharmacol Ther Toxicol 1988;26:221-4.
4. Cacciatore L, Cerio R, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: A controlled study. Drugs Exp Clin Res 1991;17:225-35.
5. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247.
6. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993;71:S116-23 [review].
7. Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994;74:125-30.
8. Suzuki Y, Masumura Y, Kobayashi A, et al. Myocardial carnitine deficiency in chronic heart failure. Lancet 1982;i:116 (letter).
9. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-4.
10. Pucciarelli G, Mastursi M, Latte S, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure. Clin Ther 1992;141:379-84.
11. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure—experimental and clinical study. Jpn Circ J 1992;56:86-94.
12. Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992;18:355-65.
13. De Pasquale B, Righetti G, Menotti A. L-carnitine for the treatment of acute myocardial infarct. Cardiologia 1990;35:591-6 [in Italian].
14. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior. J Am Coll Cardiol 1995;26:380-7.
15. Singh RB, Niaz MA, Agarwal P, et al. A randomised double-blind placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996;72:45-50.
16. Martina B, Zuber M, Weiss P, et al. Anti-arrhythmia treatment using L-carnitine in acute myocardial infarct. Schweiz Med Wochenschr 1992;122:1352-5 [in German].
17. Pola P, Savi L, Grilli M, et al. Carnitine in the therapy of dyslipidemic patients. Curr Ther Res 1980;27:208-16.
18. Abdel-Aziz MT, Abdou MS, Soliman K, et al. Effect of carnitine on blood lipid pattern in diabetic patients. Nutr Rep Int 1984;29:1071-9.
19. Anonymous. Carnitine, clue or cure? Lancet 1982;2:1027-8.
20. Fathizadeh H, Milajerdi A, Reiner Ž, et al. The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Pharm Des 2019;25:3266–81.
21. Askarpour M, Hadi A, Symonds ME, et al. Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2019;29:1151–67.
22. Asbaghi O, Kashkooli S, Amini MR, et al. The effects of L-carnitine supplementation on lipid concentrations inpatients with type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials. J Cardiovasc Thorac Res 2020;12:246–55.
23. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988;77:767-73.
24. Brevetti G, Perna S, Sabba C, et al. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997;79:777-80.
25. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24.
26. Dal Negro R, Pomari G, Zoccatelli O, Turco P. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabolic and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1986;24:453-6.
27. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1988;26:269-72.
28. Trivellato M, de Palo E, Gatti R, et al. Carnitine deficiency as the possible etiology of idiopathic mitral valve prolapse: case study with speculative annotation. Texas Heart Inst J 1984;11:370-6.
29. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998;180(1-2):33-41.
30. Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. J Child Neurol 1995;10 Suppl 2:S45-51.
31. Kothari SS, Sharma M. L-carnitine in children with idiopathic dilated cardiomyopathy. Indian Heart J 1998;50:59-61.
32. Gasser P, Martina B, Dubler B. Reaction of capillary blood cell velocity in nailfold capillaries to L-carnitine in patients with vasospastic disease. Drugs Exp Clin Res 1997;23:39-43.
33. Zhang JJ, Wu ZB, Cai YJ, et al. L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. Nutrition Journal. 2014 Nov;13:110.
34. Zhang T, Zhang L, Ke B, et al. L-carnitine ameliorated weight loss in fasting therapy: A propensity score-matched study. Complementary Therapies in Medicine. 2019 Jun;44:162-165.
35. Askarpour M, Hadi A, Miraghajani M, et al. Beneficial effects of l-carnitine supplementation for weight management in overweight and obese adults: An updated systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacological Research. 2020 01;151:104554.
36. Talenezhad N, Mohammadi M, Ramezani-Jolfaie N, et al. Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis. Clinical Nutrition ESPEN. 2020 06;37:9–23.
37. Pooyandjoo M, Nouhi M, Shab-Bihar S, et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2016;17:970–6. doi:10.1111/obr.12436.
38. Samimi M, Jamilian M,Ebrahimi FA, et al. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clinical Endocrinology. 2016 Jun;84(6):851–7.
39. Adeva-Andany M, Calvo-Castro I, Fernandez-Fernandez C, et al. Significance of l-carnitine for human health. IUBMB Life 2017;69:578–94.
40. Bene J, Hadzsiev K, Melegh B. Role of carnitine and its derivatives in the development and management of type 2 diabetes. Nutr Diabetes 2018;8:8.
41. Ramazani M, Qujeq D, Moazezi Z. Assessing the Levels of L-Carnitine and Total Antioxidant Capacity in Adults with Newly Diagnosed and Long-Standing Type 2 Diabetes. Can J Diabetes 2019;43:46-50.e41.
42. Poorabbas A, Fallah F, Bagdadchi J, et al. Determination of free L-carnitine levels in type II diabetic women with and without complications. Eur J Clin Nutr 2007;61:892–5.
43. Ringseis R, Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr 2012;51:1–18.
44. Vidal-Casariego A, Burgos-Pelaez R, Martinez-Faedo C, et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes 2013;121:234–8.
45. El-Sheikh H, El-Haggar S, Elbedewy T. Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients. Diabetes Metab Syndr 2019;13:167–73.
46. Derosa G, Maffioli P, Ferrari I, et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010;57:777–86.
47. Derosa G, Maffioli P, Salvadeo S, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010;49:1717–25.
48. Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 2009;10:1875–82.
49. Molfino A, Cascino A, Conte C, et al. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. JPEN J Parenter Enteral Nutr 2010;34:295–9.
50. Imbe A, Tanimoto K, Inaba Y, et al. Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps. Endocr J 2018;65:521–6.
51. Fathizadeh H, Milajerdi A, Reiner Z, et al. The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Excli j 2019;18:631–43.
52. Johri A, Heyland D, Hetu M, et al. Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies. Nutr Metab Cardiovasc Dis 2014;24:808–14.
53. Alipour B, Barzegar A, Panahi F, et al. Effect of L-Carnitine Supplementation on Metabolic Status in Obese Diabetic Women with Hypocaloric Diet. Health Scope 2014;3:e14615.
54. Salehpour S, Nazari L, Hoseini S, et al. Effects of L-carnitine on Polycystic Ovary Syndrome. JBRA Assist Reprod 2019;23:392–5.
55. Sima A. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 2007;21:13–23.
56. Evans J, Jacobs T, Evans E. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 2008;42:1686–91.
57. Li S, Chen X, Li Q, et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig 2016;7:777–85.
58. Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology2004;63:641-6.
59. Costa M, Canale D, Filicori M, et al. L-carnitine in idiopathic asthenozoospermia: a multicenter study. Andrologia 1994;26:155-9.
60. Vitali G, Parente R, Melotti C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res 1995;21:157-9.
61. Moncada ML, Vicari E, Cimino C, et al. Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta Europaea Fertilitatis 1992;23:221-4.
62. Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2002;67:33-8.
63. Geier DA, Kern JK, Davis G, et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit 2011;17:PI15-23.
64. Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology2004;63:641-6.
65. Kuratsune H, Yamaguti K, Takahashi M, et al. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994;18(1 suppl):S62-7.
66. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997;35:16-23.
67. Gramignano G, Lusso MR, Madeddu C, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition2006;22:136-45.
68. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006;32:551-9.
69. Cerretelli P, Marconi C. L-carnitine supplementation in humans. The effects on physical performance. Int J Sports Med 1990;11:1-14 [review].
70. Heinonen OJ. Carnitine and physical exercise. Sports Med 1996;22:109-32 [review].
71. Bucci LR. Nutrients as ergogenic aids for sports and exercise. Boca Raton, FL: CRC Press, 1993, 47-52 [review].
72. Colombani P, Wenk C, Kunz I, et al. Effects of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double blind crossover field study. Eur J Appl Physiol 1996;73:434–9.
73. Decombaz J, Deriaz O, Acheson K, et al. Effect of L-carnitine on submaximal exercise metabolism after depletion of muscle glycogen. Med Sci Sports Exerc 1993;25:733-40.
74. Trappe SW, Costill DL, Goodpaster B, et al. The effects of L-carnitine supplementation on performance during interval swimming. Int J Sports Med 1994;15:181-5.
75. Green RE, Levine AM, Gunning MJ. The effect of L-carnitine supplementation on lean body mass in male amateur body builders. J Am Dietet Assoc 1997;(suppl):A-72 [abstract].
76. Al-Biltagi M, Isa M, Bediwy AS, et al. L-Carnitine improves the asthma control in children with moderate persistent asthma. J Allergy (Cairo) 2012;2012:509730.
77. Giamberardino MA, Dragani L, Valente R, et al. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. Int J Sports Med 1996;17:320-4.
78. Gaby, AR. Nutritional Medicine. Concord, NH: Fritz Perlberg Publishing, 2011.
79. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure—experimental and clinical study. Jpn Circ J 1992;56:86-94.
80. Dipalma JR. Carnitine deficiency. Am Fam Physician 1988;38:243-51.
81. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.
82. Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999;13:251-3.
83. Del Favero A. Carnitine and gangliosides. Lancet 1988;2:337 [letter].